Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP1 | P53582 | 5/20 | 0.68 |
| ▸ | ACHE | P22303 | 1/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | HTR6 | P50406 | 1/20 | 0.48 |
| ▸ | HTR7 | P34969 | 2/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2126669 | 0.98 | METAP1 (0.68) | METAP1ACHESIGMAR1HTR6 | |
| SCHEMBL8003063 | 0.91 | METAP1 (0.71) | METAP1ACHESIGMAR1CYP19A1 | |
| SCHEMBL2125675 | 0.91 | METAP1 (0.71) | METAP1ACHESIGMAR1CYP19A1 | |
| Hydrochloric Acid SCHEMBL2125507 | 0.89 | METAP1 (0.72) | METAP1CYP19A1 | |
| SCHEMBL7586745 | 0.84 | METAP1 (0.48) | METAP1ACHESIGMAR1HTR7CYP19A1 | |
| SCHEMBL15700140 | 0.83 | ACHE (0.56) | METAP1ACHESIGMAR1HTR7CYP19A1 | |
| SCHEMBL7314737 | 0.81 | ACHE (0.49) | METAP1ACHESIGMAR1HTR7CYP19A1 | |
| SCHEMBL2175676 | 0.81 | METAP1 (1.00) | METAP1ACHECYP19A1 | |
| Hydrochloric Acid SCHEMBL9426039 | 0.80 | METAP1 (0.49) | METAP1ACHESIGMAR1HTR7CYP19A1 | |
| Hydrochloric Acid SCHEMBL2124625 | 0.80 | METAP1 (1.00) | METAP1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8278338-B2 | Saturated and unsaturated 3-pyridyl-benzocycloalkylmethyl-amines for use in treating pain, depression and/or anxiety | GRUENENTHAL GMBH (DE) | 2012-10-02 | — | — | US | disclosed |
| EP-1758860-B1 | SATURATED AND UNSATURATED 3-PYRIDYL-BENZOCYCLOALKYLMETHYL-AMINES FOR USE IN THE TREATMENT OF PAINS, DEPRESSIONS AND ANXIETY STATES | GRUENENTHAL GMBH (DE) | 2009-09-02 | — | — | EP | disclosed |
| US-20070203192-A1 | Saturated and unsaturated 3-pyridyl-benzocycloalkylmethyl-amines for use in treating pain, depression and/or anxiety | GRUENENTHAL GMBH | 2007-08-30 | — | — | US | disclosed |
| EP-1758860-A1 | SATURATED AND UNSATURATED 3-PYRIDYL-BENZOCYCLOALKYLMETHYL-AMINES FOR USE IN THE TREATMENT OF PAINS, DEPRESSIONS AND ANXIETY STATES | Grünenthal GmbH (DE) | 2007-03-07 | — | — | EP | disclosed |
| WO-2005123681-A1 | SATURATED AND UNSATURATED 3-PYRIDYL-BENZOCYCLOALKYLMETHYL-AMINES FOR USE IN THE TREATMENT OF PAINS, DEPRESSIONS AND ANXIETY STATES | Grünenthal GmbH (DE) | 2005-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203192-A1 | Saturated and unsaturated 3-pyridyl-benzocycloalkylmethyl-amines for use in treating pain, depression and/or anxiety | OPRK1, OPRM1, OPRL1 | METAP1 4249/4885ACHE 134/4885SIGMAR1 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.